Smoking Cessation Program for Lao People With HIV
Launched by UNIVERSITY OF OKLAHOMA · Jun 9, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new program designed to help people living with HIV in Laos quit smoking. Tobacco use is a major health risk, especially for those with HIV, and many smokers in Laos do not have access to reliable support to help them quit. The study will test two different ways to support smoking cessation: one using a smartphone app that provides personalized help through messages and videos, and another using printed self-help materials. Researchers want to see which method is more effective in helping people stop smoking.
To be eligible for the trial, participants need to be at least 18 years old, able to be contacted in various ways, and willing to share their progress after six months. There are no specific health conditions that would exclude someone from participating. Participants can expect to receive support through either the app or printed materials, and their success in quitting smoking will be monitored over time. This study aims to improve health care for people with HIV and reduce the risk of cancer related to smoking.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. aged ≥18 years
- • 2. reachable within 30 days of the target assessment date by different methods (up to 4 phone calls at different days and time, 3 text messages for each platform \[e.g., SMS, Telegram, or Whatsapp\], 3 emails if applicable, and via direct contact at a prescheduled clinic appointment if applicable)
- • 3. consenting to be contacted after 6 months at the enrollment and able to provide recorded verbal informed consent when contacted by the research staff to participate.
- Exclusion Criteria:
- • None.
About University Of Oklahoma
The University of Oklahoma, a leading research institution, is dedicated to advancing healthcare through innovative clinical trials and research initiatives. With a robust network of interdisciplinary experts and state-of-the-art facilities, the university fosters an environment that promotes scientific discovery and the development of new treatments. Its commitment to patient-centered research ensures that clinical trials not only adhere to the highest ethical standards but also aim to address pressing health challenges. By collaborating with various stakeholders, including industry partners and healthcare providers, the University of Oklahoma seeks to translate research findings into tangible benefits for communities, ultimately enhancing the quality of care and improving health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vientiane, , Lao People's Democratic Republic
Patients applied
Trial Officials
Phonepadith Xangsayarath, MD, PhD
Study Director
Ministry of Health of Lao PDR, National Center for Laboratory and Epidemiology
Cate Moriasi, PhD
Study Director
The University of Oklahoma Health Sciences Center (OUHSC)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported